Agilent Technologies Inc. shares approached a 52-week high on Friday, trading at $160.05, just 1% below the peak of $160.36 recorded earlier in the session. The milestone comes amid a 31.48% year-over-year gain that has pushed the company's market capitalization to roughly $45 billion.
The advance reflects a series of regulatory and product developments. The U.S. Food and Drug Administration approved Agilent's PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for several cancers, including esophageal squamous cell carcinoma. Separately, the European Union certified Agilent's PD-L1 IHC 22C3 pharmDx companion diagnostic for ovarian cancer, expanding its use with Merck's KEYTRUDA therapy.
Analysts at Jefferies resumed coverage of Agilent with a Hold rating and a $135 price target, citing the completion of the Biocare acquisition as a driver of modest revenue growth. The firm also noted that the acquisition is expected to support Agilent's position in biopharmaceutical workflow solutions.
Agilent further expanded its Altura HPLC column portfolio, introducing new columns designed for analytical workflows involving peptides, proteins, and other therapeutics in biopharmaceutical development and production. The additions aim to enhance separation and purification processes in drug discovery and manufacturing.
The stock's valuation metrics remain elevated, with a price-to-earnings ratio of 31.95. InvestingPro analysis flagged Agilent as among the most overvalued stocks based on its Fair Value assessment and noted overbought conditions indicated by the Relative Strength Index. The company's shares have gained 31.48% over the past 12 months, outpacing broader benchmarks in the life sciences and diagnostics sector.
Additional corporate updates included Cantor Fitzgerald's reiteration of an Overweight rating on Custom Truck One Source with a $13.00 price target, emphasizing the target's scalable platform and strong execution capabilities. ProPicks AI historical findings highlighted gains of 231.5% for Siemens Energy and 189% for Sandisk, underscoring the firm's data-driven investment approach.
